Stem cell therapy company Aldagen is pulling back on its plans for an initial public offering.
The Durham, N.C.-based company revealed in a filing with the Securities & Exchange Commission that it is withdrawing its IPO plans due to market conditions.”
The company in 2009 filed a registration statement seeking to raise more than $80 million to take its compounds into mid-stage clinical trials.